Navigation Links
Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Date:11/12/2012

CRANBURY, N.J., Nov. 12, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 10:30 a.m. Eastern Time.  The conference will be held at The Pierre Hotel, New York City.

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LayerBio is an MIT spin-off developing ... The National Eye Institute (NEI) at the National Institutes ... SBIR grant to develop a drug-eluting intraocular lens (IOL) ... cause of vision loss in people over age 40 ... Dr. Ken Mandell, LayerBio’s Founder and CEO, "There is ...
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... RIDGE, N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today ... mg (referred to as Somatuline®) was approved by ... the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ... locally advanced or metastatic disease to improve progression-free ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... Therapeutics, a,drug and diagnostic discovery company, has completed ... The company expects to have,this test certified and ... GLP (Good,Laboratory Practices) compliant laboratories to the pharmaceutical ... test aims to identify patients suffering from,Alzheimer,s disease ...
... Use of Hand ... NORCROSS, Ga., Nov. 8 Headlines call MRSA ... continue,to report daily on recent school closings and, in ... staph infection*. Even though,hand-washing is advocated as one of ...
... N.J., Nov. 8 Ortho Biotech,Products, L.P. today ... from the U.S. Food and Drug,Administration (FDA) to ... (ESA) class. The modifications to the label ... from the May 10th FDA Oncologic Drugs Advisory,Committee ...
Cached Biology Technology:ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 2ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 3ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 4Soap and Water May not be Enough to Fight MRSA Superbug 2Soap and Water May not be Enough to Fight MRSA Superbug 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 5
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/3/2014)... IRVINE, Calif. , Dec. 2, 2014 /PRNewswire/ ... of globally deployed, innovative test solutions for military, ... the newest version of its successful TS-900 ... the performance and features of high-end systems to ... with outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... CHICAGO New research using animal models is enabling ... addiction in humans knowledge that may lead to ... that cause people to relapse. The findings were released ... meeting and the world,s largest source of emerging news ...
... Atlanta, GA Current research suggests that latent ... The related report by Onyeagocha et al, "Latent cytomegalovirus ... issue of The American Journal of Pathology . ... in the United States. Most people who are ...
... CLEMSON Algae, not asteroids, were the key ... University researchers. Geologist James W. Castle and ecotoxicologist John ... were a deadly factor in mass extinctions millions of ... into the past but also offers a caution about ...
Cached Biology News:Studies improve knowledge of underlying brain changes caused by addiction 2The bowels of infection 2Clemson researchers say algae key to mass extinctionss 2
pETDuet-1 is designed for the coexpression of two target genes....
Mouse Laminin-1 MAb (Clone AL-3)...
IEX-1 S/L (H-20)...
... reactivity with rat (100%), mouse ... pig (48%). Slight reactivity ... confirmed by Western blot versus ... Gia-1, Gia-2, rat Gia-3, bovine ...
Biology Products: